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Abstract
Background: In Sweden, human tissue samples obtained from diagnostic and surgical procedures have for
decades been routinely stored in a formalin-fixed, paraffin-embedded, form. Through linkage with nationwide
registers, these samples are available for molecular studies to identify biomarkers predicting mortality even in slow-
progressing prostate cancer. However, tissue fixation causes modifications of nucleic acids, making it challenging to
extract high-quality nucleic acids from formalin fixated tissues.
Methods: In this study, the efficiency of five commercial nucleic acid extraction kits was compared on 30 prostate
biopsies with normal histology, and the quantity and quality of the products were compared using
spectrophotometry and Agilent’s BioAnalyzer. Student’s t-test’s and Bland-Altman analyses were performed in order
to investigate differences in nucleic acid quantity and quality between the five kits. The best performing extraction
kits were subsequently tested on an additional 84 prostate tumor tissues. A Spearman’s correlation test and linear
regression analyses were performed in order to investigate the impact of tissue age and amount of tissue on
nucleic acid quantity and quality.
Results: Nucleic acids extracted with RNeasy® FFPE and QIAamp® DNA FFPE Tissue kit had the highest quantity and
quality, and was used for extraction from 84 tumor tissues. Nucleic acids were successfully extracted from all
biopsies, and the amount of tumor (in millimeter) was found to have the strongest association with quantity and
quality of nucleic acids.
Conclusions: To conclude, this study shows that the choice of nucleic acid extraction kit affects the quantity and
quality of extracted products. Furthermore, we show that extraction of nucleic acids from archival formalin-fixed
prostate biopsies is possible, allowing molecular studies to be performed on this valuable sample collection.
Keywords: Prostate biopsies, Archival formalin-fixed paraffin-embedded tissue, Nucleic acid isolation kits, RNA
integrity number
Background
Prostate cancer (PCa) is the most common male cancer
in Europe, with almost 400,000 new diagnoses each year
[1]. The natural history of the disease is variable, ranging
from slow-growing indolent tumors to highly aggressive
lethal tumors. Even though currently used clinical fac-
tors for prostate cancer management (Gleason score,
baseline PSA levels, clinical stage and tumor extent
based on core biopsies) provide valuable information,
there is a strong need to find prognostic biomarkers that
identify patients in need of curative treatment among
men with low and intermediate-risk disease.
Finding prognostic biomarkers for PCa in prospective
studies requires large study populations with many years
of follow-up to ensure appropriate end-point data. By
conducting nested case-control studies in large reposi-
tories of archived prostatic tissue, the efficiency and
cost-effectiveness of prognostic studies can be strongly
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improved, while preserving the validity of a prospective
cohort study. In Sweden, virtually all human tissue sam-
ples obtained from diagnostic and surgical procedures
have for decades been routinely stored in formalin-fixed,
paraffin-embedded, (FFPE) form [2]. Through linkage
with nationwide registers using the unique national regis-
tration number, this vast collection of samples are avail-
able for molecular epidemiological studies to identify
biomarkers predicting mortality even in slow-progressing
prostate cancer.
Nucleic acids of high quality are vital for downstream
molecular applications, however fixation of tissues causes
modifications of biomolecules such as cross-linkage of nu-
cleic acids with proteins, covalent modifications of both
DNA and RNA, and fragmentation of RNA, making it
challenging to extract nucleic acids of high quality from
FFPE tissues [3–5]. The quality of RNA is furthermore af-
fected by several other parameters such as time from sam-
ple retrieval to fixation, duration and conditions of
fixation, the paraffin embedding procedure, sample stor-
age, and even the extraction protocol used [6–11]. Unfor-
tunately, these pre-analytical procedures cannot easily be
standardized between, or even within, laboratories, and re-
searchers can only impact the choice of extraction proced-
ure when performing studies on archival FFPE tissues.
Numerous commercially available kits for extraction of
nucleic acids from FFPE tissues exists on the market
today, however there is no general consensus among sci-
entists which extraction kit works best, as most protocols
work well. Nevertheless, it has been shown that the
quality of the extracted RNA can differ between extrac-
tion kits. Several studies have been performed compar-
ing the performance of commercial extraction kits, and
different or even discordant results have been reported
by different groups [12–16].
In order to assess the ability of five commercially avail-
able kits to obtain high-quality DNA and RNA from
FFPE tissues, we carried out four comparative trials on
archival FFPE prostate needle biopsies. Furthermore, the
best performing kits were used in order to assess the
quantity and quality of nucleic acids extracted. The re-
sults from this study will subsequently be implemented
in the Program for prediction of Mortality in prostate
cancer (PROMORT) study, investigating prognostic bio-
markers in prostate biopsy tissues (Zelic et al., submitted
manuscript).
Methods
Study population
In this study, we included FFPE prostatic needle biopsy
tissues from men who underwent prostate biopsies for
suspicion of PCa at the Department of Urology, Univer-
sity hospital in Örebro, Sweden between 1992 and 2002.
In the first part of the study, in order to assess the
performance of five commercial kits for extraction of
nucleic acids from FFPE biopsy tissues, we included 30
biopsies with normal prostatic histology. In the second
part of the study, in order to assess the quantity and
quality of the nucleic acids extracted from the FFPE bi-
opsies, we included 84 biopsies with cancer. The study
was approved by the Ethical committee in Stockholm,
Sweden (Approval number 2012/1586–31/1).
Assessment of nucleic acids extraction kits from FFPE
biopsies with normal histology
The study material, consisting of 30 FFPE prostate biop-
sies with normal histology, was randomly divided into
three different groups; 1) ten biopsies for comparison be-
tween the High Pure FFPE RNA Micro Kit (Roche Diag-
nostics, West Sussex, UK) and the RNeasy® FFPE kit
(Qiagen, Hilden, Germany), 2) ten biopsies for comparison
between the High Pure DNA FFPET Isolation Kit (Roche
Diagnostics, West Sussex, UK) and the QIAamp® DNA
FFPE Tissue kit (Qiagen, Hilden, Germany), and 3) ten bi-
opsies for comparison of the best performing DNA and
RNA kits from the two previous steps to the AllPrep®
DNA/RNA FFPE kit (Qiagen, Hilden, Germany). In order
to minimize the risk of variation due to different opera-
tors, the same operator performed all extractions with one
kit (e.g. all extractions using the RNeasy® FFPE kit).
1) In the comparison between a) the High Pure FFPE
RNA Micro kit and the RNeasy® FFPE kit and b)
the High Pure FFPET DNA Isolation kit to the
QIAamp® DNA FFPE Tissue kit, three serial
sections of 10 μm were cut from ten biopsies with
normal histology. In each case, the first section was
discarded to exclude negative effects from exposure
to air. The two remaining sections were placed on
separate slides; tissues were scraped and put in
separate Eppendorf tubes, and were subsequently
used for RNA/DNA extraction using either one of
the two different extraction kits being compared.
The extraction procedure followed the
manufacturers’ instructions. RNA was eluted with
20 μl elution buffer while DNA was eluted with
50 μl.
2) For comparison between the best performing RNA
and DNA kits and the AllPrep® DNA/RNA FFPE
kit, four serial sections of 10 μm were cut from the
third set of ten biopsies with normal histology. In
each case, the first section was discarded to exclude
negative effects from exposure to air. Each
subsequent section was placed on separate slides;
tissues were scraped, put in separate Eppendorf
tubes and were subsequently used for extraction of
nucleic acids using the three different extraction
kits. The extraction procedure followed the kit
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instructions and RNA/DNA was eluted using 20 μl
and 50 μl of elution buffer, respectively.
Assessment of DNA/RNA quantity and quality from FFPE
biopsies with cancer
The study pathologists (F.G and M.F) assessed the pros-
tatic biopsies for millimeter of tumor (tumor length),
percentage of tumor tissue and Gleason score. They also
circled tumor areas on the hematoxylin and eosin (H&E)
slides corresponding to the tissue blocks. Three slices of
10 μm were subsequently sectioned from each biopsy tis-
sue block; the first section was discarded while the
remaining two sections from each case were used for
macro-dissection of the tumor area using an RNase-free
scalpel for each case. The macro-dissected tumor area
from one tissue section was used for RNA isolation
using the RNeasy® FFPE kit (Qiagen, Hilden, Germany)
and the tumor area from the second section was used
for DNA isolation using the QIAamp® DNA FFPE Tissue
kit (Qiagen, Hilden, Germany), following the manufac-
turers’ instructions.
Quantity and quality measurements
The quantity and purity (A260/A280) of the extracted
DNA and RNA was measured using the NanoDrop
ND-2000 Spectrophotometer (Thermo Scientific, Wal-
tham, MA, USA). When using a spectrophotometer, an
OD260/280 greater than 1.8 or 2.0 is generally consid-
ered to be an indicator of good RNA and DNA quality,
respectively. Lower OD ratios could indicate the pres-
ence of contaminants, or very low concentrations (< 10
ng/μl) of nucleic acids in the sample. The RNA integrity
was assessed using the Agilent 2100 BioAnalyzer and
the Agilent RNA 6000 Pico kit (Agilent Technologies,
Palo Alto, CA). The RNA Integrity Number (RIN) is a
score of the RNA degradation ranging on a scale from 1
to 10, where 1 represents the most degraded RNA and
10 represents a completely intact RNA [17].
The endogenous control gene 18S rRNA is typically
employed to allow quantitation of relative gene expression
in DNA/RNA samples. In order to determine the presence
of amplifiable 18S rRNA in the extracted samples, a qPCR
was performed. Ten nanograms of total RNA were con-
verted to cDNA using the SuperScript VILO master mix
(Thermo Fisher Scientific, Waltham, MA, USA). The
resulting cDNA or 10 ng of DNA from each sample were
used in a qPCR reaction using a TaqMan probe for
RNA18S5 (Hs03928985_g1) and TaqMan Fast Universal
PCR Master Mix (Thermo Fisher Scientific, Waltham,
MA, USA) and run in a 40-cycle reaction on the 7900 HT
system (Applied Biosystems, Foster City, CA, USA). The
threshold value was automatically calculated using the RQ
Manager Version 1.2.1 software and CT-values of < 38
were considered positive.
Statistical analyses
For assessment of the quality and quantity of the nucleic
acids extracted with the five commercial extraction kits,
both a paired Student’s t-test and a Wilcoxon matched-
pairs signed rank test was performed in order to evaluate
differences in yields, purity (A260/A280), RIN- and CT-va-
lues between the kits. A Bland-Altman analysis was per-
formed in order to investigate the level of agreement of
the two extraction kits. A fixed difference indicates that
one method yields higher/lower values compared to the
other method by a constant amount, while a proportional
difference indicates if one method yields higher/lower
values than those from the other method, which is propor-
tional to the level of the measured variable [18].
In order to test if the percentage of tumor cells, length
of the tumor tissue, or year of biopsy were associated
with the quantity and quality of the extracted nucleic
acids, a Spearman’s correlation test was performed. A
multivariate linear regression models was performed in
order to investigate associations between tumor length
(mm), age of FFPE tissue, Gleason score and measure-
ments of RNA/DNA quantity and quality. Tumor length
and percentage of tumor cells was categorized and a
Mann-Whitney U-test or a Kruskal-Wallis one-way ana-
lysis of variance was performed in order to test for dif-
ferences in quantity and quality of nucleic acids between
the categories. All statistical analyses were performed in
SPSS Statistics version 22.
Results
Assessment of nucleic acids extraction kits
RNA extraction comparative trials
In the first trial, Roche Diagnostic’s High Pure FFPE
RNA Micro kit was compared to Qiagen’s RNeasy® FFPE
kit. The RNeasy® FFPE kit resulted in consistently higher
RNA yields (mean yield 16.3 ng/μl) ranging from 8.1 ng/
μl to 20.8 ng/μl compared to the samples extracted with
High Pure FFPE kit (mean yield 5.6 ng/μl) ranging from
2.2 ng/μl to 11.2 ng/μl (p < 0.001). Furthermore, both the
A260/A280 ratios and RIN-values in samples extracted
with the RNeasy® FFPE kit were higher (mean A260/
A280 = 1.55, mean RIN-value = 1.98) compared to sam-
ples extracted with the High Pure kit (mean A260/A80
= 1.38, mean RIN-value = 1.04) (p = 0.03 and p < 0.001,
respectively). To evaluate the quality and efficiency of
the extracted RNA, the expression levels of 18S5 rRNA
was measured by qPCR. All samples were amplifiable as
indicated by a CT-value < 38. Samples extracted with the
RNeasy® FFPE kit yielded lower CT-values compared to
samples extracted with the High Pure kit (mean CT 25.4
versus 26.4), however this difference was not statistically
significant (Table 1).
Figure 1a-c shows a comparison of RNA yields, purity
(A260/A280) and RIN-values obtained from samples
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extracted with the High Pure FFPE RNA Micro kit and
the RNeasy® FFPE kit, respectively. A fixed difference
was indicated by a mean difference of − 10.71 (limits of
agreement: − 16.96 – − 4.46) when investigating the
agreement in yields between the two kits. This observa-
tion indicates that the High Pure kit consistently pro-
duced lower yields. A fixed difference was also seen for
the purity of the extracted RNA (mean difference − 0.17;
limits of agreement: − 0.42 – 0.09) and the RIN-values
(mean difference − 0.94; limits of agreement: − 1.95 –
0.07). No proportional difference was evident for RNA
yields (slope: 0.269, p = 0.48) or purity (slope: − 0.7, p =
0.255), although a proportional difference was evident
for RIN-values (slope: 1.98, p < 0.0001).
In the second trial of comparisons, the RNeasy® FFPE
kit was compared to the RNA fraction of the samples
extracted with Qiagen’s AllPrep® DNA/RNA FFPE kit.
There was no evidence of difference in yields (11.4 ng/μl
versus 12.6 ng/μl), A260/A280 ratios (1.47 versus 1.50)
or CT-values (27.4 versus 28.0) between these two kits,
although higher RIN-values were seen for samples ex-
tracted with the RNeasy® FFPE kit (2.2 versus 1.2, p =
0.006)(Table 1). A Bland-Altman analysis indicated there
were no fixed differences in yield (mean difference 1.17;
limits of agreement: − 5.53 – 7.87) or A260/A280 ratios
(mean difference 0.03; limits of agreement: − 0.18 – 0.23).
However, a fixed difference was seen for RIN-values, with
the AllPrep® DNA/RNA FFPE kit consistently producing
lower RIN-values compared to samples extracted with the
RNeasy® FFPE kit (mean difference − 1.04; limits of agree-
ment: − 2.83 – 0.75). No proportional difference was evi-
dent for neither yield (slope: 0.318, p = 0.604), purity
(slope: − 0.583, p = 0.567), or RIN-values (slope: − 0.099,
p = 0.978) (Fig. 1d-f).
DNA extraction comparative trials
In the third comparative trial, Qiagen’s QIAamp® DNA
FFPE Tissue and Roche Diagnostic’s High Pure FFPET
DNA Isolation kit was investigated. Both kits resulted in
similar DNA yields (4.4 ng/μl versus 5.0 ng/μl). However,
samples extracted with the QIAamp® FFPE kit had
higher A260/A280 ratios compared to samples extracted
with the High Pure DNA kit (mean ratio 1.89 versus
1.37, p = 0.002). To evaluate the quality and efficiency of
Table 1 Comparison of RNA quantity and quality isolated by three different commercially available kits
RNA extraction Comparison 1 Comparison 2
High Pure RNeasy® p-value AllPrep® RNeasy® p-value
FFPE tissue input 10 μm 10 μm 10 μm 10 μm
Successful extractions 10/10 10/10 10/10 10/10
RNA yield (ng/μl)
Minimum 2.2 8.1 8.0 6.7
Maximum 11.2 20.8 16.8 16.7
Mean (95% CI) 5.6 (3.4;8.2) 16.3 (13.1;19.0) < 0.001a 12.6 (10.8;14.6) 11.4 (9.1;13.8) 0.307a
SD 3.1 3.8 2.5 3.1
A260/A280
Minimum 1.23 1.41 1.39 1.39
Maximum 1.62 1.69 1.59 1.57
Mean (95% CI) 1.38 (1.28;1.48) 1.55 (1.51;1.61) 0.003a 1.50 (1.43;1.55) 1.47 (1.43;1.52) 0.419a
SD 0.13 0.06 0.07 0.06
RIN-value
Minimum 1.0 1.0 1.0 1.0
Maximum 1.2 2.5 2.5 2.5
Median 1.0 2.15 0.011b 1.0 2.5 0.044b
IQR 0.10 0.88 0.15 0.40
CT-value RNA18S5
Minimum 21.2 23.6 26.1 24.9
Maximum 30.9 27.2 30.1 28.9
Mean (95% CI) 26.4 (23.7;28.9) 25.4 (24.3;26.3) 0.268a 28.0 (27.1;28.9) 27.4 (26.5;28.4) 0.088a
SD 3.36 1.3 1.22 1.26
Comparison of RNA quantity and quality isolated by three different commercially available kits, High Pure FFPE RNA Micro kit, RNeasy® FFPE kit and AllPrep® DNA/
RNA FFPE kit. SD Standard deviation, IQR Inter Quartile Range. a Student’s paired T-test, and b Wilcoxon matched-pairs signed rank test
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the extracted DNA, a qPCR measuring the expression
levels of 18S5 rRNA was performed, and all samples
were amplifiable as indicated by a CT-value < 38. A dif-
ference in CT –values could be seen for samples ex-
tracted with the two kits (mean CT 28.6 versus 27.1, p =
0.011), with samples extracted with the QIAamp® kit
yielding higher CT-values compared to samples extracted
with the High Pure DNA kit (Table 2). A Bland-Altman
analysis did not indicate a fixed difference for yield for
the two kits (mean difference − 0.61; limits of agreement:
− 8.03 – 6.81), however, a fixed difference was seen for
A260/A280 ratios (mean difference 0.35; limits of agree-
ment: − 0.22 – 1.17). No proportional difference was evi-
dent for either DNA yield (slope: − 1.019, p = 0.162) or
purity (slope: 0.969, p = 0.061) (Fig. 2a-b).
In the fourth and final comparative trial, the QIAamp®
DNA FFPE Tissue kit was compared to the DNA fraction
from the AllPrep® DNA/RNA FFPE kit. There was no
evidence of difference in DNA yield (mean yield 3.8 ng/μl
versus 4.4 ng/μl) for samples extracted with the two kits,
however higher A260/A280 ratios were seen in samples
extracted with the QIAamp® kit (mean ratio 1.68 versus
1.36, p < 0.001). Furthermore, samples extracted with the
AllPrep® kit yielded lower CT –values (mean CT 29.0 ver-
sus 27.3, p < 0.001) (Table 2). A Bland-Altman analysis re-
vealed a fixed difference for A260/A280 ratios (mean
difference 0.32; limits of agreement: − 0.03 – 0.68) but not
for DNA yield (mean difference − 0.6; limits of agreement:
− 2.32 – 1.12). No proportional difference was evident for
either yield (slope: − 0.158, p = 0.856) or A260/A280
(slope: − 1.646, p = 0.158) (Fig. 2c-d).
Assessment of DNA/RNA quantity and quality from
archival biopsies
In this part of the study, 84 FFPE needle prostate biopsy
tissues with malignant histology were included. Selected
Fig. 1 Bland-Altman plots for investigating the level of agreement between RNA extraction kits. Each plot shows the differences between the
two kits against the averages of the two kits. The lines represent the mean differences and upper and lower limits of agreement (LOA, mean
differences ±1.96SD). a Comparison of RNA yield (ng/μl) of samples extracted with High Pure FFPE RNA Micro Kit and RNeasy® FFPE kit. b
Comparison of purity (A260/A280) of samples extracted with High Pure FFPE RNA Micro kit and RNeasy® FFPE kit. c Comparison of RIN-values of
samples extracted with High Pure FFPE RNA Micro kit and RNeasy® FFPE kit. d Comparison of RNA yield (ng/μl) of samples extracted with
RNeasy® FFPE kit and AllPrep® DNA/RNA FFPE kit. e Comparison of purity (A260/A280) of samples extracted with RNeasy® FFPE kit and AllPrep®
DNA/RNA FFPE kit. f Comparison of RIN-values of samples extracted with RNeasy® FFPE kit and AllPrep® DNA/RNA FFPE kit
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Table 2 Comparison of DNA quantity and quality isolated by three commercially available kits
DNA extraction Comparison 1 Comparison 2
High Pure QIAamp® p-value AllPrep® QIAamp® p-value
FFPE tissue input 10 μm 10 μm 10 μm 10 μm
Successful extractions 10/10 10/10 10/10 10/10
DNA yield (ng/μl)
Minimum 1.9 1.9 3.5 2.7
Maximum 13.0 8.5 5.4 4.4
Mean (95% CI) 5.0 (2.4;7.6) 4.4 (2.7;5.6) 0.623a 4.4 (3.9;4.7) 3.8 (3.3;4.2) 0.059a
SD 3.3 1.9 0.6 0.6
A260/A280
Minimum 1.06 1.49 1.27 1.51
Maximum 1.69 2.66 1.48 1.87
Mean (95% CI) 1.37 (1.27;1.57) 1.89 (1.58;2.17) 0.002a 1.36 (1.29;1.41) 1.68 (1.62;1.79) < 0.001a
SD 0.19 0.38 0.07 0.12
CT -value RNA18S5
Minimum 24.7 27.0 26.6 27.9
Maximum 29.5 31.1 28.5 30.9
Mean (95% CI) 27.1 (26.1;28.1) 28.6 (27.4;29.2) 0.011a 27.3 (26.9;27.9) 29.0 (28.2;30.1) < 0.001a
SD 1.29 1.17 0.68 1.23
Comparison of DNA quantity and quality isolated by three commercially available kits; High Pure FFPET DNA Isolation kit, QIAamp® DNA FFPE Tissue kit, and
AllPrep® DNA/RNA FFPE kit. SD – Standard Deviation, CI – Confidence Interval. a Student’s paired T-test
Fig. 2 Bland-Altman plots for investigation of level of agreements between DNA extraction kits. Each plot shows the differences between the
two kits against the averages of the two kits. The lines represent the mean differences and upper and lower limits of agreement (LOA, mean
differences ±1.96SD). a Comparison of DNA yield (ng/μl) of samples extracted with High Pure FFPET DNA Isolation kit and QIAamp® DNA FFPE
Tissue kit. b Comparison of purity (A260/A280) of DNA samples extracted with High Pure FFPET DNA Isolation kit and QIAamp® DNA FFPE Tissue
kit. c Comparison of DNA yield (ng/μl) of samples extracted with QIAamp® DNA FFPE Tissue kit and AllPrep® DNA/RNA FFPE kit. d Comparison of
purity (A260/A280) of samples extracted with QIAamp® DNA FFPE Tissue kit and AllPrep® DNA/RNA FFPE kit
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characteristics from the biopsies can be seen in Table 3.
Based on the results from the assessment of nucleic acid
extraction kits, DNA and RNA were extracted from two
serial sections of the biopsies using the QIAamp® DNA
FFPE Tissue Kit and RNeasy® FFPE kit. Both DNA and
RNA were successfully extracted from all biopsies, with
varying quantity and quality. The mean DNA yield for
all 84 biopsies was 3.7 ng/μl (range: 0.6–12.5 ng/μl) and
the mean A260/A280 ratio was 1.8 (1.1–5.3). The mean
RNA yield was 10.6 ng/μl (1.6–30.9 ng/μl), mean A260/
A280 was 1.5 (0.7–1.9) and the RIN-values ranged from
1.0–4.1, with a mean value of 2.3. Scanned images of bi-
opsies from three patients and the resulting DNA and
RNA yield/biopsy can be seen in Fig. 3. To evaluate the
quality and efficiency of the extracted DNA and RNA, a
qPCR measuring the expression levels of 18S5 rRNA
was performed. One RNA sample and three DNA samples
failed to reach the threshold of a CT-value < 38 (Table 4).
There was evidence of correlation between tumor length
(in mm) and RNA yield (r = 0.45, p < 0.001) and
RIN-values (r = 0.37, p < 0.01) (Table 5), as well as for
tumor length and DNA yield (r = 0.45, p < 0.001) (Table 6).
When dividing tumor length into three categories (< 5
mm, 5–9mm, and ≥ 10mm), DNA/RNA yield as well as
RNA18S5 CT-values differed among categories, with
higher yields/lower CT-values with increasing tumor
length (Fig. 4). No correlation between the DNA and
RNA yield could be seen (r = 0.18, p = 0.11). A weak cor-
relation between age of the FFPE tissue and DNA yield
(r = 0.337, p < 0.01) was observed, but not RNA yield (r =
− 0.10, p = 0.928). Furthermore, there was no significant
correlation between percentage of tumor cells or Gleason
scores with DNA/RNA yield, A260/A280 ratios, RIN- or
CT-values (data not shown). A multivariate regression
analyses confirmed that tumor length was the main deter-
minant for both RNA and DNA yield, for each additional
millimeter tumor the quantity of RNA/DNA increased
with 0.53 ng/μl (95% CI: 0.18–0.88) and 0.24 ng/μl (95%
CI: 0.11–0.37), respectively. However, an association be-
tween tumor length and RIN-values was not found (β =
0.008, 95% CI: -0.03 – 0.05). Age of the FFPE tissue was
associated with DNA yield (β = 0.67, 95% CI: 0.35–0.98),
and Gleason score (β = − 0.57, 95% CI: -1.08 - -0.06).
Discussion
Assessment of nucleic acids extraction kits
We compared the quality and quantity of nucleic acid
extraction in five commercially available extraction kits,
using prostate needle biopsies with normal histology, as-
suming that normal tissue is less heterogeneous than
malignant tissue, thus reducing the risk of biased com-
parison. We found that RNA extraction with RNeasy®
had higher yields of RNA, purity (A260/A280) and
RIN-values. Furthermore, the agreement in RNA yield
and quality (A260/A280 and RIN-values) between the
two compared kits was low, with consistently lower
yields and purities in the High Pure kit. RNA of high
quality is essential when performing molecular studies,
and thus even small differences in purity and RIN-values
are important to consider when choosing extraction kit.
Based on the results in this trial, the RNeasy® kit would
be preferred for extraction of high quality RNA from
FFPE prostate biopsies.
In a second trial, the RNeasy® FFPE kit was compared
to the AllPrep® DNA/RNA FFPE kit. The two kits pro-
duced similar yields and purity of the extracted RNA,
however, higher RIN-values were found in samples ex-
tracted with the RNeasy® kit. Even though it would typic-
ally be preferable to extract both DNA and RNA from
the same tissue section, the consistently lower quality of
RNA produced with the AllPrep® kit suggests that using
two separate extraction kits for DNA and RNA would
be preferable if high quality RNA is desired.
A possible explanation for the kit-to-kit variations in
RNA quantity and quality could be the conditions rec-
ommended for the proteinase K digestion. The use of
proteinase K digestion is necessary to release RNA from
the meshwork of cross-linked proteins and nucleic acids,
and it has also been shown to play an important role in
the extraction of longer stretches of nucleic acids (>200
bp) [14, 19, 20]. However, the proteinase K digestion
does not attack the methylene bridges that forms the
crosslinks [3]. The RNeasy® kit uses a proteinase K treat-
ment for 15 min at 56 °C followed by 15min at 80 °C,
the latter being critical for reversal of crosslinks intro-
duced by formalin fixation. The High Pure kit on the
other hand recommends a proteinase K digestion for 3 h
at 55 °C. It is therefore possible that the digestion
process in the High Pure protocol is less efficient in
breaking the crosslinks in the tissue, thus resulting in
less RNA yield, which is also more fragmented than
samples extracted with the RNeasy® kit.
In a third trial, we compared the two DNA extraction
kits QIAamp® DNA FFPE Tissue kit and High Pure
FFPET DNA Isolation kit, and found similar DNA
Table 3 Selected characteristics of malignant prostate biopsies
Characteristic N = 84
Year of biopsy 1992–1998
Length of tumor, median mm (range) 4.3 (0.2–17.8)
% tumor cells (range) 40 (5–90)
Gleason score
≤ 6 4
3 + 4 9
4 + 3 15
8–10 56
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yields, although with higher purity (A260/A280) in the
QIAamp® kit. One sample extracted with the QIAamp®
kit had a high A260/A280 ratio (2.66), which is probably
due to a RNA contamination within this sample. Based
on these data, we chose the QIAamp® kit for comparison
with the AllPrep® DNA/RNA FFPE kit. In this final trial,
similar DNA yields in samples extracted with the two
kits were found, although once again with higher purity
(A260/A280) in the QIAamp®. Thus, our analyses
suggest the QIAamp® kit as the best performing DNA
extraction kit from FFPE prostate biopsies.
Assessment of DNA/RNA quantity and quality from
archival biopsies
Performing molecular studies on archival FFPE needle bi-
opsy material have potential limitations. Prostate needle
biopsies are often performed using an 18-gauge needle,
yielding a biopsy which is roughly 1mm in diameter and
12–15mm long. Sectioning such a biopsy would in theory
yield 100 sections of 10 μm. However, the biopsy has typ-
ically been sectioned previously as a part of clinical evalu-
ation, and thus only a limited amount of tissue with
representative disease histology is available for research
studies. Furthermore, according to Swedish laws one must
make sure that there is always representative cancer tissue
left after sections are taken for research studies. Thus, in
practice, it might be possible to take four to five 10 μm
sections for research studies. The aim of this second part
of the study was thus to investigate if it is possible to ex-
tract nucleic acids from archival FFPE prostate biopsies
using one 10 μm section of tissue. We also wanted to in-
vestigate the quantity and quality of the nucleic acids ex-
tracted from the biopsies in order to investigate which
type of molecular studies could be performed.
Based on the results from the assessment of nucleic acid
extraction kits, nucleic acids were extracted using the
QIAamp® DNA FFPE Tissue kit and RNeasy® FFPE kit.
DNA was successfully extracted from all 84 biopsies with
a mean yield of 3.7 ng/μl and a purity of 1.7. One DNA ex-
tract had a high A260/A280 ratio (5.3), indicating a RNA
contamination of this sample. RNA was also successfully
extracted from all 84 samples, with a mean yield of 10.6
ng/μl. The purity of the extracted RNA had a mean value
of 1.55 and the RIN-value a mean of 2.3. The expression
of 18S5 RNA showed high variability between samples, in-
dicating that this is not an optimal endogenous control
gene for prostate tissues. The amount of tumor (in milli-
meters) had the strongest association with both quantity
and quality of the nucleic acids extracted from the biop-
sies within this study, which is consistent with a previous
study showing an association between tumor amount,
measured by millimeter tumor of a renal biopsy, and
Fig. 3 Examples of DNA/RNA yield from biopsies containing varying tumor length. Tumor tissue is indicated in red. a A tumor length of 3.4 mm
yielded 4.4 ng/μl RNA and 2.8 ng/μl DNA. b A tumor length of 7.1 mm yielded 8.4 ng/μl RNA and 8.0 ng/μl DNA. c A tumor length of 12.8 mm
yielded 26.3 ng/μl RNA and 12.5 ng/μl DNA
Table 4 Quantity and quality measurements of nucleic acids
Archival biopsies RNA DNA
FFPE tissue input 10 μm 10 μm
Number of extractions 84 84
Yield (ng/μl)
Minimum 1.6 0.6
Maximum 30.9 12.5
Median 9.2 3.3
IQR 6.35 2.3
A260/A280
Minimum 0.7 1.1
Maximum 1.9 5.3
Median 1.5 1.7
IQR 0.2 0.4
RIN-value
Minimum 1.0 –
Maximum 4.1 –
Median 2.5 –
IQR 0.18
CT -value RNA18S5
Minimum 22.0 24.6
Maximum 39.3 38.7
Mean 28.8 –
SD 3.1 –
Median – 29.2
IQR – 6.4
Quantity and quality measurements of nucleic acids isolated from archival
FFPE biopsy tissues from the prostate tumor. SD Standard Deviation, IQR Inter
Quartile Range
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purity of RNA (A260/A280) [21]. Our results indicated no
correlation between age of the FFPE specimen and neither
RNA yield or integrity of the extracted RNA. This result
has been supported by several previous studies [10, 21,
22], although others have seen an association between age
of the tissue and RNA quality, but not yield [23]. However,
we did find a correlation between age of the FFPE speci-
men and DNA yield in the present study, which has also
been shown previously by Carrick et al., who observed a
significant association between DNA yield and quality and
storage time [24]. Nucleic acids extracted from FFPE sam-
ples are generally more degraded than samples from fresh
frozen material, resulting in reduced qPCR amplification
of DNA and RNA targets larger than 200 base pairs (bp)
[25–27]. In the present study, a 90 bp amplicon of 18S5
rRNA was amplified with success (CT < 38) in 83 of 84
(98.8%) RNA samples and 81 of 84 (96.4%) DNA samples.
The RNA sample that was not amplified had the lowest
purity of all samples (A260/A280 = 0.7), however for the
DNA samples there was no apparent reason to why the
amplification failed. These results indicate that archival
FFPE prostate biopsy tissues are suitable for PCR amplifi-
cation even though the small quantity and poor quality of
the isolated nucleic acids.
In order to gain new insights to pathological processes,
quantitative measures of mRNA levels and DNA analyses
investigating for example mutations, polymorphisms and
epigenetic changes have become essential. It is recom-
mended that only high-quality DNA and RNA are used
for these analyses. In some instances, however, such as in
studies of biomarkers of prostate cancer mortality, high
quality samples may not be available. Typically using
low-quality samples introduces bias toward the null, be-
cause the degradation of samples entails random varia
bility that is similar across comparison groups. Therefore,
precision and power is impaired, and the risk of false
negative associations, but not false positive, increases.
Many studies have investigated the effect of poor RNA
quality (RIN-value) and DNA quality, using techniques
such as qPCR, microarrays and NGS [10, 12, 23, 24, 26,
28–35]. RIN-values are considered the most powerful pre-
dictor of microarray quality [30]. Although moderately de-
graded RNA could yield acceptable microarray results,
extensively degraded samples such as those obtained in
the present study, should usually be excluded from ana-
lyses. Only samples with RIN-values ≥7 are normally rec-
ommended for microarray studies [36]. However, the
cDNA-mediated Annealing, Selection, extension and
Ligation (DASL) assay have been shown to tolerate input
RNA degraded to an average of 100–200 bp, while still
yielding robust results [37]. This technology has success-
fully been used to profile archival FFPE prostatic tissues
previously, including by our group [38–41]. Achieving in-
formation on single nucleotide polymorphisms (SNPs) in
FFPE DNA has been an issue due to low quantity and
quality of the DNA. However, studies comparing results
obtained from fresh frozen and FFPE tissues have shown a
high concordance for some SNP arrays [42, 43], and new
platforms have allowed generation of reliable results even
from small quantities of FFPE DNA [44]. NGS is another
technology used for both large-scale and targeted analysis
of both DNA and RNA samples, and it has been shown
that the success rate of the technique is not associated
with storage time of the FFPE tissue, not even for samples
stored up to 32 years [24]. Furthermore, a good correl-
ation of NGS data has been found between fresh frozen
and FFPE tissues, even though a higher sequencing cover-
age (× 80) is recommended for FFPE tissues [23, 31–35].
Measuring gene expression levels in FFPE samples using
qPCR has been suggested to be more robust than through
Table 5 Correlation between tumor length (mm) and RNA quantity and quality
Tumor length (mm) RNA Yield RNA A260/A280 RNA RIN-value RNA CT-value
Tumor length (mm) 1.0 0.45** 0.14 0.37** −0.25*
RNA Yield – 1.0 −0.23* 0.19 −0.04
RNA A260/A280 – – 1.0 −0.01 −0.51**
RNA RIN-value – – – 1.0 −0.29*
RNA CT-value – – – – 1.0
* Significant correlation p < 0.05. ** Significant correlation p < 0.001 using Pearson Correlation
Table 6 Correlation between tumor length (mm) and DNA quantity and quality
Tumor length (mm) DNA Yield DNA A260/A280 DNA CT-value
Tumor length (mm) 1.0 0.45** 0.16 −0.13
DNA Yield – 1.0 0.09 −0.31*
DNA A260/A280 – – 1.0 −0.11
DNA CT-value – – – 1.0
* Significant correlation p < 0.05. ** Significant correlation p < 0.001 using Pearson Correlation
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microarrays [26]. This suggestion is strengthened by find-
ings showing that RIN-values cannot be used in order to
predict performance of the qPCR [10, 26, 45, 46]. Amplifi-
cation of products > 400 bp using qPCR is strongly
dependent on good RNA quality (RIN > 5), although if
smaller amplicons (70–250 bp) are investigated, the results
are more or less independent of RNA quality [12]. In the
past it has been problematic to perform large scale qPCR
analyses on FFPE samples due to high CT-values and lim-
ited concentrations of the extracts [47, 48], however tech-
niques such as TaqMan® PreAmp has addressed this
challenge faced by researchers working with small samples
such as needle biopsies, from which only limited amounts
of RNA could be extracted. The simple process includes
pre-amplification of as little as one ng of cDNA, and en-
ables the user to perform qPCR amplification of up to 384
target genes per pre-amplification reaction on TaqMan®
low-density arrays [49]. Targeted qPCR and pyrosequenc-
ing can also be used to provide reliable data when analyz-
ing FFPE DNA samples [50], and the methods can
overcome the limits of using FFPE DNA by designing as-
says specific for small DNA fragments and improving the
PCR protocol for low DNA inputs [51, 52].
An advantage with our study is that the extraction kits
have been compared using serial sections of the same bi-
opsies, which decreases the risk of differences between
the kits due to variations in the tissue histology. Further-
more, the extraction kits were tested on biopsies with
normal histology, which further decreases tissue hetero-
geneity. The best performing extraction kits for DNA
and RNA was subsequently used for extraction of nu-
cleic acids on 84 biopsies with malignant histology,
yielding similar quantities and quality of the nucleic
acids as in the normal biopsies. The study has a number
of limitations. 1) The limited number of nucleic acid ex-
traction kits tested. Many other kits for extraction of nu-
cleic acids from FFPE tissues exist on the market, with
the potential to perform better than the kits used in this
study. 2) The small number of comparisons performed
for each extraction kit (n = 10). Further studies on larger
tissue materials are needed in order to validate the re-
sults found within the present study. 3) Even though the
tissue sections used for comparisons of extraction kits
were cut immediately adjacent to one another, there
could still have been variations in the tissue area that in-
fluenced the DNA/RNA yield. 4) Due to the limited
amount of tissue available in a prostate biopsy, extrac-
tions could not be performed in duplicates from the
same biopsy. Furthermore, two different operators per-
formed the extraction of nucleic acids with the kits to be
compared, which could have affected the outcome due
to inter-operator variability [15].
Conclusions
To conclude, our results indicate that it is possible to
utilize archival FFPE prostate biopsies in biomarker
studies for PCa, and that the choice of extraction kit
could be of importance to obtain high quality DNA and
RNA from FFPE tissues.
Fig. 4 The effect of tumor length on DNA/RNA yield and RNA18S5 CT -values. a RNA yield is increasing with increasing tumor length, (b) CT-
values on RNA samples are decreasing with increasing tumor length, (c) DNA yield is increasing with increasing tumor length, and (d) CT-values
on DNA samples are decreasing with increasing tumor length. * p < 0.05, ** p < 0.01, and ***p < 0.001 compared to < 5mm cancer
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